Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice

Vaccine

Volumn 26, Issue 36, 2008, Pages 4655-4663

  Babu, J Pradeep ^a   Pattnaik, Priyabrata ^a   Gupta, Nimesh ^a   Shrivastava, Ambuj ^a   Khan, Mohsin ^a   Rao, P V Lakshmana ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

Author keywords

Antibody isotyping; Cytokine profiling; Dengue virus; Domain III; Envelope protein; Neutralizing antibody; Splenocyte proliferation

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CONCANAVALIN A; CYTOKINE; DENGUE VACCINE; FREUND ADJUVANT; IMMUNOLOGICAL ADJUVANT; MONTANIDE ISA 720; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENGUE VIRUS; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SPLEEN CELL; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; CELL PROLIFERATION; CYTOKINES; DENGUE VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREUND'S ADJUVANT; HUMANS; LYMPHOCYTES; MANNITOL; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; OLEIC ACIDS; PLAQUE ASSAY; SPLEEN; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 48649102965     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.006     Document Type: Article

References (67)

1. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10 2 (2002) 100-103
2. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11 3 (1998) 480-496
3. Holmes E.C., and Burch S.S. The causes and consequences of genetic variation in dengue virus. Trends Microbiol 8 2 (2000) 74-77
4. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60 (2003) 421-467
5. Burke D.S., and Kliks S. Antibody-dependent enhancement in dengue virus infections. J Infect Dis 193 4 (2006) 601-603
6. Hombach J., Barrett A.D., Cardosa M.J., Deubel V., Guzman M., Kurane I., et al. Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health. Vaccine 23 21 (2005) 2689-2695
7. Thullier P., Demangel C., Bedouelle H., Megret F., Jouan A., Deubel V., et al. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol 82 8 (2001) 1885-1892
8. Modis Y., Ogata S., Clements D., and Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci 100 12 (2003) 6899-6901
9. Hermida L., Bernardo L., Martin J., Alvarez M., Prado I., Lopez C., et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24 16 (2006) 3165-3171
10. Hung J.J., Hsieh M.T., Young M.J., Kao C.L., King C.C., and Chang W. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol 78 (2004) 378-388
11. Crill W.D., and Roehrig R.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75 (2001) 7769-7773
12. Bhardwaj S., Holbrook M., Shope R.E., Barrett A.D.T., and Watowich S.J. Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol 75 (2001) 4002-4007
13. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3 (1997) 866-871
14. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.-X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow feverdengue virus tetravalent vaccine. J Virol 75 (2001) 7290-7304
15. Guirakhoo F., Pugachev K., Arroyo J., Miller C., Zhang Z.-X., Weltzin R., et al. Viraemia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment and antibody responses against wild-type dengue virus isolates. Virology 298 (2002) 146-159
16. Sun W., Edelman R., Kanesa-Thasan N., Eckels K.H., Putnak J.R., King A.D., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 69 6 (2003) 24-31
17. Guy B., Chanthavanich P., Gimenez S., Sirivichayakul C., Sabchareon A., Begue S., et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. Vaccine 22 27/28 (2004) 3563-3574
18. Sabchareon A., Lang J., Chanthavanich P., Yoksan S., Forrat R., Attanath P., et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 23 2 (2004) 99-109
19. Putnak R., Barvir D.A., Burrous J.M., Dubois D.R., D'Andrea V.M., Hoke C.H., et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174 6 (1996) 1176-1184
20. Eckels K.H., and Putnak R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res 61 (2003) 395-418
21. Putnak R., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 35 (2005) 4442-4452
22. Mangada M.M., and Rothman A.L. Altered cytokine responses of dengue-specific CD4+ T cells to heterologous serotypes. J Immunol 4 (2005) 2676-2683
23. Innis B.L., and Eckels K.H. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med Hyg 6 (2003) 1-4
24. Blaney Jr. J.E., Hanson C.T., Firestone C.Y., Hanley K.A., Murphy B.R., and Whitehead S.S. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 6 (2004) 811-821
25. Durbin A.P., Whitehead S.S., McArthur J., Perreault J.R., Blaney Jr. J.E., Thumar B., et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 5 (2005) 710-718
26. Kochel T.J., Raviprakash K., Hayes C.G., Watts D.M., Russell K.L., Gozalo A.S., et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 27 (2000) 3166-3173
27. Raviprakash K., Marques E., Ewing D., Lu Y., Phillips I., Porter K.R., et al. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF. Virology 1 (2001) 74-82
28. Fonseca B.A., Pincus S., Shope R.E., Paoletti E., and Mason P.W. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 5 (1994) 480
29. Men R., Wyatt L., Tokimatsu I., Arakaki S., Shameem G., Elkins R., et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 27 (2000) 3113-3122
30. Huang C.Y., Butrapet S., Tsuchiya K.R., Bhamarapravati N., Gubler D.J., and Kinney R.M. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development. J Virol 21 (2003) 11436-11447
31. Staropoli I., Clement J.M., Frenkiel M.P., Hofnung M., and Deubel V. Dengue virus envelope glycoprotein can be secreted from insect cells as a fusion with the maltose-binding protein. J Virol Methods 2 (1996) 179-189
32. Staropoli I., Frenkiel M.P., Megret F., and Deubel V. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 17/18 (1997) 1946-1954
33. Thalhamer J., Leitner W., Hammerl P., and Brtko J. Designing immune responses with genetic immunization and immunostimulatory DNA sequences. Endocrine Regul 35 (2001) 143-166
34. Assad S., and Francis A. Over a decade of experience with a Yeast recombinant hepatitis B vaccine. Vaccine 18 (1999) 57-67
35. Koya V., Moayeri M., Leppla S.H., and Daniell H. Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun 12 (2005) 8266-8274
36. Chichester, Musiychuk K., de la Rosa P., Horsey A., Stevenson N., Ugulava N., et al. Immunogenicity of a subunit vaccine against Bacillus anthracis. Vaccine 16 (2007) 3111-3114
37. Devi Y.S., Mukherjee P., Yazdani S.S., Shakri A.R., Mazumdar S., Pandey S., et al. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice. Vaccine 28 (2007) 5166-5174
38. Kelly E.P., Greene J.J., King A.D., and Innis B.L. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18 (2000) 2549-2559
39. Konishi E., Kosugi S., and Imoto J. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24 (2006) 2200-2207
40. Khanam S., Rajendra P., Khanna N., and Swaminathan S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol 7 (2007) 10
41. Simmons M., Nelson W.M., Wu S.J., and Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58 (1998) 655-662
42. Simmons M., Murphy G.S., and Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2 (2001) 159-161
43. Khanam S., Etemad B., Khanna N., and Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg 2 (2006) 266-277
44. Chin J.F.L., Chu J.J.H., and Ng M.L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect 9 (2007) 1-6
45. Pattnaik P., Babu J.P., Verma S.K., Tak V., and Rao P.V. Bacterially expressed and refolded envelope protein (domain III) of dengue virus type-4 binds heparan sulfate. J Chromatogr B 1/2 (2007) 184-194
46. Russell P.K., Nisalak A., Sukhavachana P., and Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99 2 (1967) 285-290
47. Cox J.C., and coulter A.R. Adjuvants-a classification and review of their modes of action. Vaccine 3 (1997) 248-256
48. Pye D., Vandenberg K.L., Dyer S.L., Irving D.O., Goss N.H., Woodrow G.C., et al. Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. Vaccine 9 (1997) 1017-1023
49. Brewer J.M., Conacher M., Hunter C.A., Mohrs M., Brombacher F., and Alexander J. Aluminium hydroxide adjuvant initiates strong antigenspecific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. J Immunol 163 (1999) 6448-6454
50. Brewer J.M., Conacher M., Satoskar M., Bluethmann H., and Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 26 (1996) 2062-2066
51. Grun J.L., and Maurer P.H. Different T helper cell subsets elicited in mice utilising two different adjuvant vehicles: the role of endogenous IL-1 in proliferative responses. Cell Immunol 121 (1989) 134-145
52. Putnak R., Feighny R., Burrous J., Cochran M., Hackett C., Smith G., et al. Dengue-1 virus envelope glycoprotein gene expressed in recombinant baculovirus elicits virus-neutralizing antibody in mice and protects them from virus challenge. Am J Trop Med Hyg 45 (1991) 159-167
53. Delenda C., Staropoli I., Frenkiel M.P., Cabanié L., and Deubel V. Analysis of C-terminally truncated dengue 2 and dengue 3 virus envelope glycoproteins: processing in insect cells and immunogenic properties in mice. J Gen Virol 75 (1994) 1569-1578
54. Mota J., Acosta M., Argotte R., Figueroa R., Méndez A., and Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23 (2005) 3469-3476
55. Zhang Z.S., Yan Y.S., Weng Y.W., Huang H.L., Li S.Q., He S., et al. High-level expression of recombinant dengue virus type 2 envelope domain III protein and induction of neutralizing antibodies in BALB/C mice. J Virol Methods 143 (2007) 125-131
56. Srivastava A.K., Putnak J.R., Warren R.L., and Hoke Jr. C.H. Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. Vaccine 11 (1995) 1251-1258
57. Hermida L., Rodriguez R., Lazo L., Silva R., Zulueta A., Chinea G., et al. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier, enables a functional immune response against the virus in mice. J Virol Methods 115 (2004) 41-49
58. Roitt I., Brostoff J., and Male D. Immunology. 6th ed. (2001), Mosby Publications, London
59. Zhou A., Paranjape J.M., Der S.D., Williams B.R., and Silverman R.H. Interferon action in triply deficient mice reveals the existence of alternative antiviral pathways. Virology 2 (1999) 435-440
60. Huang S., Hendriks W., Althage A., Hemmi S., Bluethmann H., Kamijo R., et al. Immune response in mice that lack the interferon-gamma receptor. Science 5102 (1993) 1742-1745
61. Stojdl D.F., Abraham N., Knowles S., Marius R., Brasey A., Lichty B.D., et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol 20 (2000) 9580-9585
62. Shi Y.J., Jiang Z.Y., and Zeng K. Effect of IL-6 and TNF-alpha on Dengue virus infection of human dendritic cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 4 (2006) 469-471
63. Kurane I., Janus J., and Ennis F.A. Dengue virus infection of human skin fibroblasts in vitro production of IFN-beta, IL-6 and GM-CSF. Arch Virol 1/2 (1992) 21-30
64. Flint S.J., Enquist L.W., Racaniello, and Skalka A.M. Principles of virology, molecular biology, pathogenesis, and control of animal viruses (2000), ASM Press pp. 531-594
65. Mosmann T.R., and Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7 (1989) 145-173
66. Borish L., and Rosenwasser L.J. Update on cytokines. J Allergy Clin Immunol 3 (1996) 719-733
67. Megret F., Hugnot J.P., Falconar A., Gentry M.K., Morens D.M., Murray J.M., et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 187 (1992) 480-491